Third Arc Bio'a biotech platform provides transformational therapies for solid tumors and Inflammation & Immunology diseases. They are able to create immune synapses to activate or inhibit T cells, providing medical companies with multifunctional antibodies to help treat immune system diseases. Third Arc Bio was founded in 2022 by Sanjaya Singh and is headquartered in Boston, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/16/2024 | Series A | $165MM | $xx.xx | $305.43MM | Vida Ventures, Cormorant Asset Management, Hillhouse Investment, Omega Funds, Goldman Sachs, BVF Partners, T. Rowe Price Associates, Janus Henderson Investors, abrdn, Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, AbbVie Ventures | |
Price per Share
$xx.xx
Shares Outstanding
78,414,570
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Vida Ventures, Cormorant Asset Management, Hillhouse Investment, Omega Funds, Goldman Sachs, BVF Partners, T. Rowe Price Associates, Janus Henderson Investors, abrdn, Marshall Wace, Foresite Capital, Logos Capital, Freepoint Capital Group, AbbVie Ventures
|
||||||
01/01/2022 | Series Seed-2 | $15MM | $xx.xx | $107.47MM | Omega Funds | |
Price per Share
$xx.xx
Shares Outstanding
5,380,520
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Omega Funds
|
||||||
01/01/2022 | Series Seed | $17.75MM | $xx.xx | $107.47MM | Omega Funds | |
Price per Share
$xx.xx
Shares Outstanding
17,750,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Omega Funds
|